Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- California Verbal Learning Test- 2nd Edition (CVLT-II): Learning and Memory
研究概览
简要总结
We will explore the use of Huperzine A in patients who have sustained a moderate to severe Traumatic Brain Injury. We aim to determine whether Huperzine A, as compared with placebo, would have an effect on memory function after TBI. Additionally, we aim to determine whether use of Huperzine A in these patients can change brain activity (as indexed by EEG and Transcranial Magnetic Stimulation - TMS), and reduce prevalence/frequency of post-traumatic seizures. We also aim to evaluate the safety of Huperzine A in this population as compared with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged 18 to 65
- •Moderate or severe TBI, based on admission Emergency Room GCS 3-12
- •All subjects will be greater than 2 weeks, but no more than 1 year, after the qualifying TBI, and will be symptomatic at enrollment (i.e. all subjects will exhibit evidence of ongoing posttraumatic amnesia via the Galveston Orientation Amnesia test (GOAT), or score at least 1.5 SD below the mean for completion time on Part B of the Trail Making Test.
- •Agreement to undergo no changes in concomitant medications (including dietary supplements) or therapeutic interventions during the first 12 weeks of the study (that is, the 12 weeks of dosing with study drug), except where medically indicated. Stable concomitant drug regimen (greater than two weeks pre-enrollment without changes)
- •Normal swallowing
- •English-speaking (since not all of the outcome metrics are normed outside of the English language)
- •Patient can be on seizure medication.
排除标准
- •Patients taking acetylcholinesterase inhibitors and other cholinergic and anticholinergic drugs (e.g., tacrine, physostigmine, velnacrine, donepezil, rivastigmine, metrifonate) and CYP1A inducing drugs.
- •Evidence of more than 1 seizure in the past 4 weeks prior to enrollment: Patients may not be enrolled if there is evidence of more than one seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) during the 4 weeks prior to enrollment.
- •Premorbid history of epilepsy with seizure frequency >1 per month: Patients with a history of idiopathic epilepsy may not be enrolled if their seizure frequency was > 1 per month in the 3 months prior to injury. If pre-injury seizure frequency was < 1 per month but there is documented evidence that post-injury seizure frequency is > 1 per month or there is documented evidence of an increase in the severity or duration of a single seizure relative to the premorbid history, the patient must be excluded.
- •Evidence of premorbid major CNS disorder, developmental disorder, psychiatric disorder or substance abuse: Prior to sustaining TBI, patient was diagnosed and/or treated for a major neurologic condition, pervasive developmental disorder (e.g., mental retardation, autism), psychiatric disorder or substance abuse that continued to produce functional disability up to the time of injury.
- •Individuals with disorders of consciousness, as defined at the time of screening of having vegetative and/or minimally conscious state, will not be enrolled. However, these patients may be followed until they:
- •Meet eligibility criteria
- •Are more than 12 weeks post injury
- •Are discharged
- •Pregnancy, as determined by urine hCG testing before randomization
- •Breast feeding females
- •Significant hematologic, renal or hepatic dysfunction [Hepatic/renal dysfunction is generally identified as lab results > two times the upper limits of normal (ULN), and hematologic dysfunction is determined by clinically significant abnormal lab results], on baseline laboratory examination.
- •Slow heart rate (bradycardia) or other heart conditions related to rate
- •History of peptic ulcer disease
- •History of asthma or emphysema
- •History of GI/urinary tract blockages (i.e. ileus, IBS)
- •History of glaucoma
研究组 & 干预措施
Huperzine A
Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
干预措施: Huperzine A (Drug)
Placebo
Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
干预措施: Placebo (Drug)
结局指标
主要结局
California Verbal Learning Test- 2nd Edition (CVLT-II): Learning and Memory
时间窗: Baseline, 6 weeks, 12 weeks, 24 weeks and at 52 weeks.
Measure of learning and memory function. Three indices of the CVLT-II were calculated. The full name, abbreviated name, and the minimum and maximum possible scores of each index are indicated below: 1. California Verbal Learning Test- 2nd Edition- Total Learning \[CVLT-II-TL\] (Minimum score=0; Maximum score= 80) 2. California Verbal Learning Test- 2nd Edition- Short delay free recall \[CVLT-II-SDFR\] (Minimum score=0; Maximum score=16) 3. California Verbal Learning Test- 2nd Edition- Long delay free recall \[CVLT-II-LDFR\] (Minimum score=0; Maximum score=16) High scores are indicative of greater memory and learning for each index (i.e. better outcome).
次要结局
- Amplitude of Event Related Potentials (ERPs) P50 and P300(Baseline, 12 Weeks)
- Latency of Event Related Potentials (ERPs) P50 and P300(Baseline, 12 weeks)
- Number of Participants Who Experienced Post-traumatic Seizure During 12-week Treatment Window(Baseline and weekly for 12 weeks.)
- Number of Participants With Self-reported Side Effects During 12-week Treatment Window(Baseline and weekly for 12 weeks.)
研究者
Ross D. Zafonte, MD
Principal Investigator
Spaulding Rehabilitation Hospital